)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Cessatech
Cessatech (CESSA) investor relations material
Cessatech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Advanced paediatric pipeline with new CT004 program in collaboration with Rigshospitalet; Phase II study initiated and global rights retained.
Achieved milestone with first commercial batch of CT001 released in the U.S., enabling launch activities with initial hospitals.
European regulatory process for CT001 ongoing after negative CHMP opinion; re-examination process initiated with EMA.
Maintains focus on capital efficiency and partner-driven commercialisation model.
Financial highlights
Net revenue for Q2 2026 was DKK 0, compared to DKK 1,243,000 in Q2 2025.
Operating result for Q2 2026 was DKK -3,469,000, nearly unchanged from DKK -3,554,000 in Q2 2025.
Net loss for Q2 2026 was DKK -2,773,000, similar to DKK -2,785,000 in Q2 2025.
Cash at bank at period end was DKK 2,348,000, down from DKK 15,051,000 at Q2 2025 end.
Total equity as of 30 June 2026 was DKK 6,393,000.
Outlook and guidance
Company expects minimal clinical and CMC costs for CT001 for the remainder of 2026 as development concludes.
Loan facility of DKK 10,000,000 extended to 2027, supporting U.S. launch and providing financial flexibility.
Cash position does not include the loan facility or expected tax return due in Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cessatech
- CT001 nears commercialization; Q1 loss narrows, cash position remains strong.CESSA
Q1 2026 - CT001 advanced to regulatory review, financials improved, but going concern risk persists.CESSAQ4 2025
- CT001 advanced to EMA review, with Q3 loss and cash boosted by a successful share issue.CESSAQ3 2025
- Strong clinical results and capital raise drive regulatory and commercial progress for CT001.CESSAQ2 2025
- Proveca deal, clinical progress, and improved Q3 results position Cessatech for future growth.CESSAQ3 2024
- Q2 2024 saw no revenue, a DKK -3.4M loss, and key progress toward CT001's US launch.CESSAQ2 2024
- Net loss narrowed and cash strengthened as Cessatech advanced CT001 toward commercialization.CESSAQ4 2024
- Q1 2025 saw Cessatech advance CT001 toward EMA submission, with net loss in line with expectations.CESSAQ1 2025
Next Cessatech earnings date
Q3 202626 Nov, 2026
Cessatech
Next Cessatech earnings date
Q3 202626 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage